Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2025)

Amylyx Pharmaceuticals has reported Retained Earnings over the past 5 years, most recently at -$751.4 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$751.4 million for Q4 2025, down 816668.48% from a year ago — trailing twelve months through Dec 2025 was -$751.4 million (down 816668.48% YoY), and the annual figure for FY2025 was -$751.4 million, down 816668.48%.
  • Retained Earnings for Q4 2025 was -$751.4 million at Amylyx Pharmaceuticals, down from $815000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for AMLX hit a ceiling of $815000.0 in Q3 2025 and a floor of -$751.4 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$257.8 million (2022), compared with a mean of -$255.7 million.
  • Biggest five-year swings in Retained Earnings: crashed 3935877.78% in 2022 and later skyrocketed 100.14% in 2025.
  • Amylyx Pharmaceuticals' Retained Earnings stood at $9000.0 in 2021, then crashed by 3935877.78% to -$354.2 million in 2022, then surged by 100.06% to $197000.0 in 2023, then tumbled by 146.7% to -$92000.0 in 2024, then crashed by 816668.48% to -$751.4 million in 2025.
  • The last three reported values for Retained Earnings were -$751.4 million (Q4 2025), $815000.0 (Q3 2025), and -$684.0 million (Q2 2025) per Business Quant data.